Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Shareholder Meeting (April 2024)
41 slides from Hyphens Pharma International's shareholder meeting presentation, Apr 25, 2024
Slide 1: 6th Annual General Meeting
HYPHENS PHARMA INTERNATIONAL LIMITED 6th ANNUAL GENERAL MEETING 25 April 2024
Slide 2: Disclaimer
DISCLAIMER • This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). • This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentati
Slide 3: Agenda
AGENDA 01 FY2023 Group Overview 02 Business Updates 03 Financial Results 04 Commitment to Sustainability 05 Business Outlook
Slide 4: FY2023 Group Overview
gq Hyphens 01 FY2023 GROUP OVERVIEW
Slide 5: Group Performance
GROUP PERFORMANCE 170.6m 95.9m 3.6sg cents FY2023 Revenue (SGD) 2H2023 Revenue (SGD) Special Interim Dividend +5.1% YoY +28.4% HoH 8.6m 5.1m 0.86sg cents FY2023 PAT (SGD) 2H2023 PAT (SGD) Proposed FY2023 Final Dividend -24.6% YoY +45.7% HoH Singapore’s Leading Specialty and Consumer Healthcare Group
Slide 6: Segments and Presence
SEGMENTS AND PRESENCE Specialty Pharma Proprietary Medical Hypermart Principals Brands and Digital Sales contribution Others FY2023 25% Malaysia 11% 10% Revenue 102.2m 60% 25.7m 42.7m Singapore SGD 15% 50% Vietnam 29% 2% 28% EBITDA 9.5m 3.8m 0.2m SGD 70% EBITDA 9% 15% 1% Margin 5 14 >9000 Omnichanne
Slide 7: Business Updates
& Hyphens 02 BUSINESS UPDATES
Slide 8: Business Updates
BUSINESS UPDATES Successful registration DocMed’s partnership with Addition of products from Hoang Duc to establish Laboratoires Gilbert S.A.S. in of Nabota® in Malaysia business in Vietnam 10 territories Feb 2023 Apr 2023 May 2023 Jul 2023 Aug 2023 Signed sub-license and supply agreement to develop
Slide 9: Business Updates (Con'd)
BUSINESS UPDATES (CON’D) Licensing Wynzora® Cream for ASEAN countries from Partnership with 7-Eleven MC2 Therapeutics Acquisition of to offer Ocean Health® Ardence Pharma supplements Sdn Bhd Oct 2023 Nov 2023 Jan 2024 Feb 2024 Mar 2024 Official launch of Nabota ® Establishment of Entrance of Ceradan
Slide 10: Financial Results
& Hyphens O3 FINANGIAL RESULTS
Slide 11: Overall Performance
OVERALL PERFORMANCE +5.1% YoY -24.6% YoY Revenue SGD'm +28.4% HoH Profit After Tax SGD’m 180.0 170.6 12.0 11.4 +45.7% HoH 162.3 160.0 10.0 140.0 121.0 125.9 8.6 116.3 H2 8.0 120.0 95.9 6.6 6.7 100.0 6.0 H2 80.0 5.1 4.4 60.0 4.0 40.0 H1 2.0 H1 74.7 20.0 3.5 - - 2019 2020 2021 2022 2023 2019 2020 2021
Slide 12: Specialty Pharma Principals
Specialty Pharma Principals Revenue SGD’m 13% CAGR 102.2 95.7 62.0 62.0 65.6 2019 2020 2021 2022 2023 Singapore’s Leading Specialty and Consumer Healthcare Group
Slide 13: Proprietary Brands
Proprietary Brands Revenue SGD’m 15% CAGR 25.7 23.4 19.1 18.1 14.5 2019 2020 2021 2022 2023 Singapore’s Leading Specialty and Consumer Healthcare Group
Slide 14: Rewarding Shareholders
REWARDING SHAREHOLDERS Dividend and Dividend Yield(a) 5 16.50% 18.0% 4.5 16.0% 4 14.0% 3.5 12.0% 3 10.0% 2.5 8.0% 2 6.0% 1.5 3.7% 4.10% 1 2.30% 2.50% 4.0% 0.5 2.0% 1 0.62 0.67 1.11 4.46 0 0.0% 2019 2020 2021 2022 2023(b) Dividend （Sg cents) Dividend Yield (a) Dividend Yield is computed based on tota
Slide 15: Commitment to Sustainability
04 COMMITMENT TO SUSTAINABLITY
Slide 16: Our Commitments to Sustainability
OUR COMMITMENTS TO SUSTAINABILITY Customer Health and Safety Packaging waste Talent Management We’re proud to be awarded Best Partner for 440 20% 174 People and Planet full time increase in new hires in by our principal Chiesi employee headcount YoY FY2023 Corporate Governance Our goal is to develop
Slide 17: Supporting Local Communities
SUPPORTING LOCAL COMMUNITIES
Slide 18: Business Outlook
& Hyphens - | 05 BUSINESS OUTLOOK
Slide 19: Business Outlook
BUSINESS OUTLOOK Medical Hypermart and Proprietary Brands Specialty Pharma Portfolio Digital To unlock brand equity value and Actively looking into market Exciting opportunities in grow its presence penetration and expansion Malaysia and Vietnam Appointed proprietary brands Driving growth for medica
Slide 20: New Growth Horizon
NEW GROWTH HORIZON The Medical Aesthetic business of Hyphens Group will be carried out under the brand Ardence, under the leadership of Hyphens Group COO and Ardence Aesthetics CEO, Mr. Yann Alain Marche and Ardence Aesthetics Commercial Director, Mr. Sean Loo. Hyphens Group Ardence Aesthetics COO,
Slide 21: Questions & Answers
Questions & Answers
Slide 22: Resolutions
RESOLUTIONS
Slide 23: Resolution 1
RESOLUTION 1 To receive and adopt the Directors’ Statement and Audited Financial Statements of the Company for the financial year ended 31 December 2023 together with the Auditors’ Report thereon.
Slide 24: Resolution 2
RESOLUTION 2 To declare a final tax exempt (one-tier) dividend of 0.86 Singapore cents per ordinary share for the financial year ended 31 December 2023.
Slide 25: Resolution 3
RESOLUTION 3 To re-elect Mr. Heng Wee Koon, who is retiring in accordance with Regulation 97 of the Company’s Constitution, as a Director of the Company.
Slide 26: Resolution 4
RESOLUTION 4 To re-elect Mr. Ng Eng Leng, who is retiring in accordance with Regulation 97 of the Company’s Constitution, as a Director of the Company.
Slide 27: Resolution 5
RESOLUTION 5 To re-elect Mr Chan Kiat, who is retiring in accordance with Regulation 97 of the Company’s Constitution, as a Director of the Company.
Slide 28: Resolution 6
RESOLUTION 6 To approve the Directors’ fees of SGD257,000 for the year ended 31 December 2023.
Slide 29: Resolution 7
RESOLUTION 7 To re-appoint RSM SG Assurance LLP as auditors of the Company and to authorise the Directors to fix their remuneration.
Slide 30: Resolution 8
RESOLUTION 8 To authorise the Directors to allot and issue new shares pursuant to Section 161 of the Companies Act 1967 and Rule 806 of the SGX-ST Listing Manual Section B: Rule of Catalist.
Slide 31: Resolution 9
RESOLUTION 9 To authorise the Directors to grant awards and issue shares in accordance with Hyphens Performance Share Plan.
Slide 32: Resolution 10
RESOLUTION 10 To approve the proposed participation of Mr. Lim See Wah, the Chairman, Chief Executive Officer and a Controlling Shareholder in the Hyphens Performance Share Plan.
Slide 33: Resolution 11
RESOLUTION 11 To approve the proposed grant of 2,137,118 share awards to Mr. Lim See Wah, the Chairman, Chief Executive Officer and a Controlling Shareholder of the Company in accordance with the Hyphens Performance Share Plan.
Slide 34: Resolution 12
RESOLUTION 12 To authorise the Directors to grant options and to allot and issue shares in accordance with Hyphens Employee Share Option Scheme.
Slide 35: Resolution 13
RESOLUTION 13 To approve the proposed renewal of the share buy-back mandate.
Slide 36: Time for a Break
TIME FOR A BREAK
Slide 37: Poll Results
POLL RESULTS
Slide 38: Poll Results
POLL RESULTS Resolutions Votes in Favour Votes Against Total Votes No. of Shares % No. of Shares % No. of Shares 1. To receive and adopt the Directors’ Statement and Audited Financial Statements of the Company 253,110,500 99.95 132,000 0.05 253,242,500 for the financial year ended 31 December 2023 t
Slide 39: Poll Results
POLL RESULTS Resolutions Votes in Favour Votes Against Total Votes No. of No. of Shares % Shares % No. of Shares 5. To re-elect Mr Chan Kiat, who is retiring in accordance with Regulation 97 of the 253,039,500 99.95 132,000 0.05 253,171,500 Company’s Constitution, as a Director of the Company. 6. To
Slide 40: Poll Results
POLL RESULTS Resolutions Votes in Favour Votes Against Total Votes No. of Shares % No. of Shares % No. of Shares 9. To authorise the Directors to grant awards and issue shares in accordance with Hyphens 247,391,000 97.95 5,187,800 2.05 252,578,800 Performance Share Plan. 10. To approve the proposed
Slide 41: Thank You
THANK YOU Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Shareholder Meeting (April 2024) on 6ix